ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 740

Select Soluble Inflammatory Mediators Are Detected Prior to and Increase At Systemic Lupus Erythematosus Classification

Melissa E. Munroe1, Jourdan R. Anderson2, Julie M. Robertson3, Timothy B. Niewold4, George C. Tsokos5, Michael P. Keith6, John B. Harley7 and Judith A. James8, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, 5Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, 6Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, 7Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, 8Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation; Oklahoma University Health Sciences Center, Oklahoma City, OK

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: cytokines, Inflammation, interferons, interleukins (IL) and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation I

Session Type: Abstract Submissions (ACR)

Background/Purpose: The processes that lead to clinical illness in systemic lupus erythematosus (SLE) years before diagnosis are not well characterized.  Several cytokines have been associated with increased activity in established disease after diagnosis. This study evaluates the temporal relationship between autoantibody production, cytokine levels and the onset of SLE clinical disease.

Methods: Serial sera from 60 SLE cases before diagnosis with no ACR criteria to SLE classification (average timespan= 4.4 years) were obtained from the Department of Defense Serum Repository (DODSR). Sera samples were tested for C-reactive protein (hs-CRP), Von Willebrand’s Factor (VWF) and 32 soluble inflammatory mediators, including cytokines, chemokines, and soluble receptors using xMAP multiplex bead-based assays or sandwich ELISA (BLyS, APRIL, hs-CRP, and VWF). In addition, samples were assessed for the presence of SLE-associated autoantibodies, including Ro, La, nRNP, Sm, Ribosomal P, dsDNA, and ANA by ELISA and immunofluorescence. Interferon (IFN) activity was assessed by a cell reporter assay measuring interferon responsive gene expression (MX1, PKR, and IFIT1) by serum.

Results:

Patient samples before ACR classification had significant (p ≤ 0.01) alterations in 16 soluble mediators of inflammation, as well as VWF and hs-CRP. Levels of particular TNF Receptor (TNFR) family members, TNFRI, TNFRII, BLyS, and APRIL, dramatically increased as lupus classification approached (levels at clinical symptoms versus pre-clinical sera, p ≤ 0.001). The increase in these TNFR mediators affecting B-lymphocyte activation parallels the accumulation of autoantibodies seen leading up to diagnosis in SLE cases. Interferon (IFN)-associated mediators of inflammation are also of particular interest and were assessed. An initial evaluation of 20 SLE cases from this study revealed a significant increase in IFN activity leading up to diagnosis (p = 0.0279). We find a similar pattern of increased IFN-γ, IP-10, MIG, and MIP-1α (p ≤ 0.01) leading up to diagnosis. Mediators such as VWF, hs-CRP, stem cell factor and resistin also increase over the pre-clinical course to SLE transition (p ≤ 0.01). Inflammatory mediators IL-12 and IL-17 were significantly elevated (p ≤ 0.01) in pre-clinical samples compared with first ACR criterion and lupus classification.

Conclusion: Before SLE patients transition to clinical disease, they have significantly elevated levels of soluble inflammatory mediators. Further elevation of select markers occurs between early clinical symptoms and classified disease. That these alterations are present prior to the transition to active SLE suggests that multiple perturbations in immune-mediated inflammatory processes occur long before clinical classification and suggest that high-risk, pre-clinical individuals, destined to become SLE patients, can be identified before their illness is clinically manifested and damaging.


Disclosure:

M. E. Munroe,
None;

J. R. Anderson,
None;

J. M. Robertson,
None;

T. B. Niewold,
None;

G. C. Tsokos,
None;

M. P. Keith,
None;

J. B. Harley,
None;

J. A. James,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/select-soluble-inflammatory-mediators-are-detected-prior-to-and-increase-at-systemic-lupus-erythematosus-classification/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology